Sanofi SA (SNY)
51.26
-1.59
(-3.01%)
USD |
NASDAQ |
Nov 06, 16:00
51.25
-0.01
(-0.02%)
After-Hours: 20:00
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 128.52B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | 18.05% |
Valuation | |
PE Ratio | 25.97 |
PE Ratio (Forward) | Upgrade |
PS Ratio | 2.419 |
Price to Book Value | 1.649 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | 2.037 |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | -- |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 33.52% |
Profile
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue. |
URL | https://www.sanofi.com |
Investor Relations URL | https://www.sanofi.com/en/investors |
HQ State/Province | N/A |
Sector | Health Care |
Industry | Pharmaceuticals |
Equity Style | Large Cap/Blend |
Next Earnings Release | Jan. 31, 2025 (est.) |
Last Earnings Release | Oct. 25, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | May. 09, 2024 |
Ratings
Profile
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue. |
URL | https://www.sanofi.com |
Investor Relations URL | https://www.sanofi.com/en/investors |
HQ State/Province | N/A |
Sector | Health Care |
Industry | Pharmaceuticals |
Equity Style | Large Cap/Blend |
Next Earnings Release | Jan. 31, 2025 (est.) |
Last Earnings Release | Oct. 25, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | May. 09, 2024 |